Billionaire Ken Fisher's investment firm, Fisher Investments, has significant stakes in Eli Lilly and Company (LLY), a pharmaceutical leader in treatments for diabetes, cancer, and other serious conditions. According to 13F filings, the company owns approximately 4.9 million shares of LLY, valued at over $4.4 billion. Ken Fisher's investment strategy emphasizes growth stocks, but he has recently expressed optimism about value stocks outperforming growth stocks in the near future.

Eli Lilly and Company (LLY) has a strong pipeline targeting diabetes, cancer, and neurodegenerative diseases, with multiple therapies in late-stage clinical trials expected to further accelerate growth. The company's leadership in diabetes care is solidified by the success of Mounjaro, which has seen significant demand for obesity management.

However, LLY recently reported underwhelming Q3 2024 earnings, missing estimates and underperforming forecasts. Despite this, analysts anticipate a rebound in Q4, with projected normalized EPS of $5.48 and revenue of $14 billion.

Source: https://ca.finance.yahoo.com/news/eli-lilly-company-lly-ken-192708238.html